{"id":"streptococcus-pneumoniae-serotype-3","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine works by presenting the serotype 3 capsular polysaccharide antigen conjugated to a protein carrier (typically CRM197 or similar), which enhances T-cell dependent immune responses. This stimulates both antibody production and cellular immunity against S. pneumoniae serotype 3, providing protection against invasive pneumococcal disease caused by this serotype.","oneSentence":"This is a pneumococcal conjugate vaccine containing serotype 3 polysaccharide antigen conjugated to a protein carrier to stimulate immune response against Streptococcus pneumoniae serotype 3 infection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:38:11.710Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive pneumococcal disease caused by Streptococcus pneumoniae serotype 3"},{"name":"Prevention of pneumococcal pneumonia caused by serotype 3"}]},"trialDetails":[{"nctId":"NCT07181200","phase":"","title":"Urine Pneumococcal Antigen Project","status":"NOT_YET_RECRUITING","sponsor":"Liverpool School of Tropical Medicine","startDate":"2025-10","conditions":"Pneumonia, Pneumonia - Bacterial","enrollment":350},{"nctId":"NCT04078997","phase":"","title":"An Evaluation of PCV13 Vaccine Schedules, Comparing Impact of 2+1 vs 3+0 on Pneumococcal Carriage in Blantyre, Malawi","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2019-07-21","conditions":"13-valent Pneumococcal Vaccine, Streptococcus Pneumoniae","enrollment":3507},{"nctId":"NCT06879327","phase":"PHASE2","title":"Infant Malaria Vaccine Schedule Optimization","status":"RECRUITING","sponsor":"PATH","startDate":"2025-05-30","conditions":"Malaria Vaccines","enrollment":1200},{"nctId":"NCT07035054","phase":"PHASE2","title":"Phase Ⅱ Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2024-04-20","conditions":"Streptococcus Pneumoniae Pneumonia","enrollment":992},{"nctId":"NCT07025876","phase":"EARLY_PHASE1","title":"PhaseⅠClinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2023-11-18","conditions":"Streptococcus Pneumoniae Pneumonia","enrollment":240},{"nctId":"NCT00622843","phase":"PHASE3","title":"Pneumococcal Conjugate Vaccination in HIV in Comparison to Polysaccharide Vaccine Boosting","status":"COMPLETED","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2002-12","conditions":"HIV Infections, Streptococcus Pneumoniae","enrollment":275},{"nctId":"NCT06731374","phase":"PHASE4","title":"Carriage to Assess Protection of New Pneumococcal Vaccines - PCV15","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2025-02-24","conditions":"Pneumococcal Disease, Pneumococcal Carriage","enrollment":106},{"nctId":"NCT03848065","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-04-02","conditions":"Pneumococcal Infections","enrollment":133},{"nctId":"NCT05477693","phase":"PHASE4","title":"Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide Vaccine","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2022-10-25","conditions":"Pneumococcal Infections","enrollment":1800},{"nctId":"NCT03565900","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-09-12","conditions":"Pneumococcal Infections","enrollment":277},{"nctId":"NCT03692871","phase":"PHASE3","title":"A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-12-14","conditions":"Pneumococcal Infections","enrollment":2409},{"nctId":"NCT04016714","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-08-28","conditions":"Pneumococcal Infections","enrollment":1191},{"nctId":"NCT03620162","phase":"PHASE3","title":"A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-18","conditions":"Pneumococcal Infections","enrollment":900},{"nctId":"NCT05535868","phase":"NA","title":"Experimental Human Pneumococcal Challenge With SPN3","status":"UNKNOWN","sponsor":"Liverpool School of Tropical Medicine","startDate":"2022-08-01","conditions":"Streptococcus Pneumonia","enrollment":117},{"nctId":"NCT03480802","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-07-06","conditions":"Pneumococcal Infections","enrollment":302},{"nctId":"NCT03896477","phase":"PHASE3","title":"Study of 10-valent Pneumococcal Conjugate Vaccine (Pneumosil) Administered in a 2+1 Schedule to Healthy Infants","status":"COMPLETED","sponsor":"PATH","startDate":"2019-07-18","conditions":"Pneumonia, Pneumococcal","enrollment":660},{"nctId":"NCT04637425","phase":"PHASE3","title":"Effect of Bacterial Lysate on Nasal Carriage of Staphylococcus Aureus","status":"COMPLETED","sponsor":"Medical University of Lublin","startDate":"2018-04-22","conditions":"Allergic Rhinitis","enrollment":70},{"nctId":"NCT04802616","phase":"PHASE3","title":"The Influence of Nonspecific Immunostimulation on Changes in the Concentration of iNKT Cells","status":"COMPLETED","sponsor":"Medical University of Lublin","startDate":"2021-03-22","conditions":"Allergic Rhinitis Due to Grass Pollen","enrollment":80},{"nctId":"NCT01436396","phase":"PHASE3","title":"Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-09-07","conditions":"Dengue, Dengue Hemorrhagic Fever, Yellow Fever","enrollment":792},{"nctId":"NCT01411241","phase":"PHASE3","title":"Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-07-18","conditions":"Dengue, Dengue Hemorrhagic Fever","enrollment":720},{"nctId":"NCT03480763","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-06-22","conditions":"Pneumococcal Infections","enrollment":652},{"nctId":"NCT04912297","phase":"","title":"Immunity to Serotype 19A Streptococcus Pneumoniae in Children Vaccinated With PCV10","status":"COMPLETED","sponsor":"Finnish Institute for Health and Welfare","startDate":"2009-11-12","conditions":"Pneumococcal Infections","enrollment":186},{"nctId":"NCT03731182","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-01-23","conditions":"Pneumococcal Infections","enrollment":104},{"nctId":"NCT04875858","phase":"PHASE4","title":"Immunogenicity After Revaccination With 23-valent Pneumococcal Polysaccharide Vaccine: Healthy Elderly People Versus Diabetic Patients","status":"UNKNOWN","sponsor":"Korea University Guro Hospital","startDate":"2021-05-01","conditions":"Pneumococcal Infections","enrollment":254},{"nctId":"NCT04270552","phase":"PHASE3","title":"Efficacy Of Bacterial Lysate In Children With Allergic Rhinitis","status":"COMPLETED","sponsor":"Medical University of Lublin","startDate":"2018-04-22","conditions":"Allergic Rhinitis","enrollment":76},{"nctId":"NCT03547167","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-07-16","conditions":"Pneumococcal Infections","enrollment":1515},{"nctId":"NCT01735084","phase":"PHASE4","title":"Using Pneumococcal Vaccines in Combination for Maximum Protection From Ear and Lung Infections in First 3 Years of Life","status":"COMPLETED","sponsor":"Menzies School of Health Research","startDate":"2013-03-12","conditions":"Otitis Media, Febrile Illness, Cough","enrollment":261},{"nctId":"NCT02787863","phase":"PHASE4","title":"Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology","status":"COMPLETED","sponsor":"Mikhael Petrovich Kostinov","startDate":"2012-09-06","conditions":"Chronic Obstructive Pulmonary Disease, Asthma, Pneumococcal Infections","enrollment":219},{"nctId":"NCT02987972","phase":"PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-03-21","conditions":"Pneumococcal Infections","enrollment":1051},{"nctId":"NCT02097472","phase":"PHASE1, PHASE2","title":"Dose-Finding Study of S.Pneumoniae Whole Cell Vaccine Adsorbed to Alum (PATH-wSP) in Healthy Kenyan Adults and Toddlers","status":"COMPLETED","sponsor":"PATH","startDate":"2014-04","conditions":"Pneumonia, Pneumococcal","enrollment":304},{"nctId":"NCT02573181","phase":"PHASE2","title":"Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-10-30","conditions":"Pneumococcal Infections","enrollment":253},{"nctId":"NCT02037984","phase":"PHASE1, PHASE2","title":"Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-01-28","conditions":"Streptococcus Pneumoniae Infection, Pneumococcal Infections","enrollment":341},{"nctId":"NCT01215188","phase":"PHASE2","title":"A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-10-14","conditions":"Pneumococcal Infections","enrollment":1152},{"nctId":"NCT02547649","phase":"PHASE2","title":"Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-10-08","conditions":"Pneumococcal Infections","enrollment":690},{"nctId":"NCT02531373","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-09-15","conditions":"Pneumococcal Infections","enrollment":338},{"nctId":"NCT01215175","phase":"PHASE1","title":"Safety and Tolerability Study for the Pneumococcal Conjugate Vaccine V114 Versus Prevnar™ (V114-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-09-25","conditions":"Pneumococcal Infections","enrollment":150},{"nctId":"NCT01513551","phase":"PHASE2","title":"The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-03-13","conditions":"Pneumococcal Infections","enrollment":692},{"nctId":"NCT01174849","phase":"PHASE4","title":"Pneumococcal Vaccines Early and in Combination","status":"COMPLETED","sponsor":"Menzies School of Health Research","startDate":"2011-08","conditions":"Otitis Media","enrollment":425},{"nctId":"NCT01214837","phase":"PHASE3","title":"Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-10","conditions":"Meningococcal Disease, Meningococcal Meningitis","enrollment":751},{"nctId":"NCT02116998","phase":"PHASE2","title":"Safety, Tolerability, and Efficacy Study of Prophylactic S. Pneumoniae Vaccine Following Challenge With S. Pneumoniae","status":"COMPLETED","sponsor":"Genocea Biosciences, Inc.","startDate":"2014-09","conditions":"Pneumococcal Infections, Pneumonia, Pneumococcal","enrollment":98},{"nctId":"NCT03405805","phase":"","title":"Immunological Memory Against Pneumococcus Induced by 3 Infant PCV 13 Vaccination Schedules","status":"UNKNOWN","sponsor":"Aghia Sophia Children's Hospital of Athens","startDate":"2016-12-12","conditions":"Immunogenicity, Vaccine, Immunologic Memory","enrollment":60},{"nctId":"NCT00133549","phase":"PHASE2","title":"9-valent CRM 197 Pneumococcal","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2000-11","conditions":"Pneumococcal Infection","enrollment":180},{"nctId":"NCT02123433","phase":"PHASE3","title":"Serological Response to Antipneumococcal Vaccination and Impact on Streptococcus Pneumoniae Nasal Carriage in HIV Adults","status":"COMPLETED","sponsor":"University of Siena","startDate":"2011-12","conditions":"HIV Infection, Pneumococcal Infections","enrollment":50},{"nctId":"NCT01619462","phase":"PHASE3","title":"Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines in Papua New Guinean Children","status":"UNKNOWN","sponsor":"Papua New Guinea Institute of Medical Research","startDate":"2011-11","conditions":"Pneumonia, Meningitis, Bacteraemia","enrollment":200},{"nctId":"NCT00508742","phase":"PHASE3","title":"Study Evaluating the Impact of a 13-valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-12","conditions":"Pneumococcal Infections","enrollment":1866},{"nctId":"NCT01414504","phase":"PHASE2","title":"Pneumococcal Conjugate Vaccine Followup","status":"COMPLETED","sponsor":"William Pomat","startDate":"2009-12","conditions":"Immune Tolerance","enrollment":280},{"nctId":"NCT00170612","phase":"PHASE2","title":"Pneumococcal Vaccination of Fiji Infants","status":"COMPLETED","sponsor":"University of Melbourne","startDate":"2005-11","conditions":"Pneumococcal Infections","enrollment":552}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":88,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SPN3","pneumococcus serotype 3"],"phase":"marketed","status":"active","brandName":"Streptococcus pneumoniae serotype 3","genericName":"Streptococcus pneumoniae serotype 3","companyName":"University of Oxford","companyId":"university-of-oxford","modality":"Biologic","firstApprovalDate":"","aiSummary":"Streptococcus pneumoniae serotype 3 is a target of polysaccharide conjugated to Corynebacterium diphtheriae CRM197 vaccine antigen. This vaccine component is used in vaccines such as Prevenar, Prevenar 13, and Prevenar 20, which are indicated for conditions including Pneumococcal Infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}